"Among people who are overweight or obese, it is those with excess fat around their abdomen who are at the greatest risk of developing an abnormal lipid profile, type 2 diabetes and ultimately heart disease," said Dr. Wael Al Mahmeed, Vice President of the Emirates Cardiac Society.

"Rimonabant is an important advance in the treatment of cardio-metabolic risk factors which contribute to the global risk for diabetes and cardiovascular disease," Al Mahmeed added.

The launch of Acomplia will also feature an evening symposium for UAE doctors on the risks of abdominal obesity.